A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation
Wlodarczyk, Zbigniew; Vanrenterghem, Yves; Krämer, Bernhard ket al.
[en] Background: This multicenter phase II study in renal transplantation compared 3 concentration-controlled ranges
of FK778 (manitimus) with mycophenolate mofetil (MMF) both given in combination with tacrolimus and
corticosteroids.
Methods: 364 patients were randomized to 12-month treatment: high-level FK778 group (H, N = 87) received
4x600mg/day (4 days) followed by 120 mg/day; mid-level FK778 group (M, N = 92) received 3x600mg/day (3 days)
followed by 110 mg/day, low-level FK778 group (L, N = 92) received 2x600mg/day (2 days) followed by 100 mg/day,
and control group received MMF 1 g/day (MMF, N = 93). After week 6, FK778 doses were adjusted to trough ranges
of 75–125 μg/mL (H), 50–100 μg/mL (M) and 25–75 μg/mL (L). Tacrolimus and steroids were administered at the
same dose in each of the 4 groups.
Results: Biopsy proven acute rejection (BPAR) at 24 weeks, the primary study endpoint, was comparable in the
L (22.8%) and MMF (17.2%) groups but higher in the H (34.5%) and M (29.3%) groups. BPAR at 12 months was
comparable in the L (23.9%) and MMF (19.4%) groups but higher in the H (34.5%) and M (31.5%) groups. Graft and
patient survival were lowest in the H group and renal function was poorest in the H and M groups. Premature
study withdrawal was highest in the H group.
Conclusions: Efficacy was similar between the low-level FK778 and MMF groups. Increased FK778 exposure was
poorly tolerated and did not improve efficacy.
Disciplines :
Surgery
Author, co-author :
Wlodarczyk, Zbigniew
Vanrenterghem, Yves
Krämer, Bernhard k
SQUIFFLET, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Ostrowski, Marek
Language :
English
Title :
A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation
FK-778 Astellas. Kaplan MJ, Current Opinion in Investigational Drugs 2005 6 526 536 15912968 (Pubitemid 40613976)
Development of a novel drug for transplantation: current results and future perspectives. Schorlemmer HU, Transplant Proc 2001 33 2425 2428 10.1016/S0041-1345(01)02060-7 11377581 (Pubitemid 33762761)
Experiences with leflunomide in solid organ transplantation. Williams JW, Mital D, Chong A, et al. Transplantation 2002 73 358 366 10.1097/00007890- 200202150-00008 11884931 (Pubitemid 34174284)
Treatment of renal allograft polyoma BK virus infection with leflunomide. Josephson MA, Gillen D, Javaid B, et al. Transplantation 2006 81 704 710 10.1097/01.tp.0000181149.76113.50 16534472
Synergism of the malonitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Lindner JK, Zantl L, Transpl Int 1998 11 303 S309 9665002
Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts. Qi Z, Simanaitits M, Ekberg H, Transpl Immunol 1999 7 169 175 10.1016/S0966-3274(99)80036-7 10608300
The effects of FK778 in combination with tacrolimus and steroids: A phase II multicenter study in renal transplant patients. Vanrenterghem Y, van Hooff JP, Klinger M, et al. Transplantation 2004 78 9 14 15257032
The Banff 97 working classification of renal allograft pathology. Racusen LC, Solez K, Colvin RB, et al. Kidney Int 1999 55 713 723 10.1046/j.1523-1755. 1999.00299.x 9987096 (Pubitemid 29082898)
Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1year. Mendez R, Gonwa T, Yang HC, et al. Transplantation 2005 80 303 309 10.1097/01.tp.0000167757.63922.42 16082323 (Pubitemid 41129957)